

해외 바이오의약품 임상 현황 (2019.8.13~2019.8.19)

한국바이오의약품협회, 2019.8.20
출처: ClinicalTrials.gov

○ 미국 9건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03851081	Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia	Allogeneic Hematopoietic Stem Cell Transplantation Recipient Blasts 5 Percent or More of Bone Marrow Nucleated Cells Blasts 5 Percent or More of Peripheral Blood White Cells CD22 Positive Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells Lymphoblasts 20 Percent or More of Peripheral Blood White Cells Recurrent B Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia	Biological: Inotuzumab Ozogamicin Other: Quality-of-Life Assessment Drug: Vincristine Sulfate Liposome	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2
NCT03735589	Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Stage II Fallopian Tube Cancer AJCC v8 Stage II Ovarian Cancer AJCC v8 Stage II Primary Peritoneal Cancer AJCC v8 Stage IIA Fallopian Tube Cancer AJCC v8 Stage IIA Ovarian Cancer AJCC v8 Stage IIA Primary Peritoneal Cancer AJCC v8 Stage IIB Fallopian Tube Cancer AJCC v8 Stage IIB Ovarian Cancer AJCC v8 Stage IIB Primary Peritoneal Cancer AJCC v8 Stage III Fallopian Tube Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Primary Peritoneal Cancer AJCC v8 Stage IIIA Fallopian Tube Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Primary Peritoneal Cancer AJCC v8 Stage IIIA1 Fallopian Tube Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Fallopian Tube Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Fallopian Tube Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Primary Peritoneal Cancer AJCC v8 Stage IIIC Fallopian Tube Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Primary Peritoneal Cancer AJCC v8 Stage IV Fallopian Tube Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IV Primary Peritoneal Cancer AJCC v8 Stage IVA Fallopian Tube Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVA Primary Peritoneal Cancer AJCC v8 Stage IVB Fallopian Tube Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Stage IVB Primary Peritoneal Cancer AJCC v8	Biological: Alpha-type-1 Polarized Dendritic Cells Biological: Autologous Natural Killer Cell-like CTLs	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04047810	Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)	Chronic Obstructive Pulmonary Disease	Biological: Mesenchymal Stem Cells	Mayo Clinic	Phase 1
NCT03950414	A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Kidney Transplant Recipients	Cytomegalovirus Infections Kidney Transplant Infection	Biological: CMV specific T-cells	University of Wisconsin, Madison University of Wisconsin Program for Advanced Cell Therapy (PACT) University of Wisconsin School of Medicine and Public Health (UWSPH) UW Health	Phase 1
NCT03878927	CPX-351+GO in Subjects 55 Years Old, or Older, With AML	Acute Myeloid Leukemia	Drug: CPX-351 Drug: Gemtuzumab Ozogamicin	Weill Medical College of Cornell University Jazz Pharmaceuticals Pfizer	Phase 1
NCT03807063	Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant	Acute Bilineal Leukemia Minimal Residual Disease Myelodysplastic/Myeloproliferative Neoplasm Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Myeloproliferative Neoplasm Recurrent Acute Biphenotypic Leukemia Recurrent Acute Lymphoblastic Leukemia Recurrent Acute Myeloid Leukemia Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome	Biological: Rivogenlecleucel Drug: Rimiducid	University of Washington National Cancer Institute (NCI) Belllicum Pharmaceuticals	Phase 1
NCT03798301	Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells	CMV Infection Cytomegalovirus Infections CMV Viremia Opportunistic Infections	Biological: CMV-specific T-cells	University of Wisconsin, Madison University of Wisconsin Program for Advanced Cell Therapy (PACT) University of Wisconsin Carbone Cancer Center (UWCCC) University of Wisconsin School of Medicine and Public Health (UWSPH) UW Health	Phase 1
NCT03381183	IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma	Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Metastatic Squamous Cell Carcinoma Oral Cavity Squamous Cell Carcinoma Oropharynx Squamous Cell Carcinoma Paranasal Sinus Squamous Cell Carcinoma Hypopharynx Squamous Cell Carcinoma Larynx Squamous Cell Carcinoma	Drug: Durvalumab Drug: IRX-2 Regimen	H. Lee Moffitt Cancer Center and Research Institute	Phase 1
NCT03346135	Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma	Plasma Cell Myeloma Secondary Amyloidosis	Procedure: Autologous Hematopoietic Stem Cell Transplantation Drug: Melphalan Biological: Daratumumab Other: Laboratory Biomarker Analysis	City of Hope Medical Center Janssen, LP	Phase 2

해외 바이오의약품 임상 현황 (2019.8.13~2019.8.19)

한국바이오의약품협회, 2019.8.20
출처: ClinicalTrials.gov

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04000594	A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease	Huntingtons Disease	Drug: RO7234292 (RG6042)	Hoffmann-La Roche	Phase 1

○ 중국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03392311	Efficacy and Safety of AD-MSCs Plus Calcipotriol Ointment in Patients With Moderate to Severe Psoriasis	Mesenchymal Stromal Cells Psoriasis Drug Effect Drug Toxicity	Drug: Calcipotriol ointment Biological: adipose-derived multipotent mesenchymal stem cells	Guangdong Provincial Hospital of Traditional Chinese Medicine	Phase 1 Phase 2
NCT04004819	Rituximab for Multiple System Atrphy	Multiple System Atrophy	Drug: Rituximab	First Affiliated Hospital of Fujian Medical University	Phase 2